Calcitonin Gene‐Related Peptide ( CGRP ) Levels of Children and Adolescents With Migraine: A Systematic Review and Meta‐Analysis of Observational Studies
Calcitonin Gene-Related Peptide (CGRP)-Spiegel bei Kindern und Jugendlichen mit Migräne: systematische Übersichtsarbeit und Metaanalyse beobachtender Studien
European Journal of Pain · 2026-01 · 30 (1)
DOI: 10.1002/ejp.70177 ↗Auf einen Blick
Die Metaanalyse fand erhöhte CGRP-Spiegel bei Kindern mit Migräne im Vergleich zu Kontrollen. Die Evidenz war je nach Analyse von moderat bis sehr niedrig.
Fragestellung
Besteht bei pädiatrischer Migräne ein Zusammenhang zwischen Blut-CGRP-Spiegeln und Migräne?
Methode
Systematische Übersichtsarbeit und Metaanalyse beobachtender Studien aus PubMed, Web of Science, Embase, CNKI und WanFang; Qualität nach Newcastle–Ottawa Scale, Evidenz nach GRADE.
Ergebnisse
8 eingeschlossene Studien. CGRP-Spiegel waren höher als bei Kontrollen (SMD 1,44; 95 %-KI 0,61–2,31). Iktal: SMD 2,39; 95 %-KI 0,59–4,19. Interiktal: SMD 1,27; 95 %-KI 0,54–1,99.
Einschränkungen
Die Autoren nennen die Notwendigkeit hochwertiger longitudinaler Studien zur Validierung.
Schlussfolgerung der Autor:innen
Die Autoren schlussfolgern, dass CGRP ein potenzieller diagnostischer Biomarker und prophylaktisches Therapieziel bei pädiatrischer Migräne sein könnte.
Kernaussagen
- CGRP-Spiegel bei Migräne höher als bei Kontrollen
- Effekt auch in iktaler und interiktaler Phase
- Hochwertige longitudinale Studien zur Validierung nötig
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Pain, online erschienen am 28.11.2025. Verfasst von Guoliang Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background and Objective Although calcitonin gene‐related peptide (CGRP) has emerged as a promising therapeutic target in migraine management, current clinical evidence regarding its dynamic variations in paediatric migraine populations remains inconclusive. We conducted a meta‐analysis to explore the relationship between blood CGRP levels and paediatric migraine. Databases and Data Treatment We systematically searched for observational studies that reported CGRP levels in paediatric migraine published in English from the PubMed, Web of Science, and Embase electronic databases, or in Chinese from the Chinese National Knowledge Infrastructure and the WanFang Med database. The Newcastle–Ottawa Quality Assessment Scale was used to assess the quality of the included studies. The quality of evidence for each outcome was assessed according to the Grading of Recommendations, Assessment, Development, and Evaluation guidelines.
Results
Of the 1134 identified studies, eight were eligible for inclusion. There was a ‘Moderate’ level of evidence demonstrating significantly elevated CGRP levels in children with migraine compared to controls (standardised mean difference [SMD] = 1.44, 95% CI 0.61–2.31). Stratification analysis showed the ‘Low’ level of evidence revealed higher levels during both ictal (SMD = 2.39, 95% CI 0.59–4.19) and interictal phases (SMD = 1.27, 95% CI 0.54–1.99). ‘Very low’ quality of evidence supported paediatric migraine patients with (SMD = 1.47, 95% CI 0.67–2.27) and without (SMD = 1.11, 95% CI 0.50–1.72) aura had higher CGRP levels than non‐migraine controls.
Conclusions
Our findings suggest that CGRP levels may be a potential diagnostic biomarker and prophylactic therapeutic target for paediatric migraine, but need high‐quality longitudinal studies to validate. Significance Statement This systematic review and meta‐analysis provides significant evidence that CGRP levels serve as a potential diagnostic biomarker for migraine in children and adolescents. Future research should further explore the diagnostic value of CGRP levels in this population. However, the current evidence does not confirm CGRP as an acute‐phase therapeutic target for pediatric and adolescent migraine, necessitating validation through higher‐quality studies. Trial Registration PROSPERO number: CRD42025635332
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
- Department of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.
ORCID-Profile: Guoliang Zhu, Juan Luo
Zitieren
APA
Zhu, G., Yan, G., Luo, Y., & Luo, J. (2026). Calcitonin Gene‐Related Peptide ( CGRP ) Levels of Children and Adolescents With Migraine: A Systematic Review and Meta‐Analysis of Observational Studies. European Journal of Pain, 30(1). https://doi.org/10.1002/ejp.70177
Vancouver
Zhu G, Yan G, Luo Y, Luo J. Calcitonin Gene‐Related Peptide ( CGRP ) Levels of Children and Adolescents With Migraine: A Systematic Review and Meta‐Analysis of Observational Studies. European Journal of Pain. 2026;30(1). doi:10.1002/ejp.70177
BibTeX
@article{Zhu2026,
author = {Zhu, Guoliang and Yan, Guifang and Luo, Ying and Luo, Juan},
title = {Calcitonin Gene‐Related Peptide ( CGRP ) Levels of Children and Adolescents With Migraine: A Systematic Review and Meta‐Analysis of Observational Studies},
journal = {European Journal of Pain},
year = {2026},
volume = {30},
number = {1},
doi = {10.1002/ejp.70177}
}
EUVIMED